GlassScriptPhysician profile
Rubindeep R Powar
NPI 1295045631
$5,017.94
in general payments reported to CMS, 2019-2025
30 companies · $870 in 2025
The $870 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.56 · 2020: $496 · 2021: $931 · 2022: $905 · 2023: $1,041 · 2024: $677 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,587.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $940.45 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $922.22 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $850.20 | 2020-2025 | |
| Amgen INC. | $389.46 | 2020-2025 | Otezla, Otezla, Repatha |
| Inspire Medical Systems, INC. | $255.41 | 2023-2025 | Inspire |
| Lilly USA, LLC | $168.82 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Janssen Pharmaceuticals, INC | $155.52 | 2020-2021 | |
| Exact Sciences Corporation | $145.82 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $144.96 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Cerapedics INC. | $140.34 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.84 | 2020-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $94.50 | 2022-2025 | |
| Amarin Pharma, INC. | $59.37 | 2020-2021 | |
| Novo Nordisk INC | $55.29 | 2023-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.57 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.98 | 2020-2021 | |
| Ardelyx, INC. | $42.78 | 2025 | Ibsrela |
| Philips North America LLC | $40.37 | 2022-2024 | (Cm9) Amb Mon & Diag Und |
| Nestle Healthcare Nutrition INC. | $39.41 | 2021-2023 | |
| Coloplast Corp | $36.96 | 2022 | |
| Mylan Specialty L.P. | $36.44 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $35.14 | 2020-2022 | |
| Genentech USA, INC. | $33.14 | 2021 | |
| Edwards Lifesciences Corporation | $27.65 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Allergan, INC. | $17.50 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $16.57 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.76 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $14.22 | 2020 | |
| Evoke Pharma, INC. | $12.22 | 2020 | |
| Daiichi Sankyo INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubindeep Powar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.